← News
Nov 13, 2025 Psychedelics
A Microdosed LSD Trial for Depression Didn't Beat Placebo
MindBio Therapeutics Corp.'s (CSE: MBIO) take-home, self-titrated microdose LSD looked strong in an open-label Phase 2a study — a 65% symptom reduction. But the controlled Phase 2b, 89 patients tested against an active placebo at the University of Auckland, didn't separate from placebo at all. Worth sitting with: open-label results are the least reliable kind, and a real control arm is where a lot of psychedelic optimism goes to get tested.
Read at MindBio Therapeutics